NEW YORK (MedscapeWire) May 03 In 2 independent, randomized trials described in the April issue of the Journal of the American Academy of Dermatology, topical pimecrolimus was safe and effective in treating atopic dermatitis in children and adolescents.
"The ascomycin derivative pimecrolimus (ASM 981) is a cell-selective cytokine inhibitor, specifically developed for the treatment of inflammatory skin diseases," write Lawrence F. Eichenfield, MD, from the University of California, San Diego, and colleagues. "Pimecrolimus cream 1% had a rapid onset of action, with significant effects observed within the first week of treatment."
In 2 independent 6-week, multicenter studies of identical design, investigators pooled data from 403 children with predominantly moderate atopic dermatitis randomized to treatment with topical pimecrolimus cream 1% or vehicle.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!